GGrantIndex
← Leaderboards

Nasser Khaled Altorki

Weill Medical Coll Of Cornell Univ

Google Scholar ↗PubMed ↗ORCID ↗
$2,970,612
Attributed
$7,961,946
Total exposure
12
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,617,272 · 13

By mechanism

U54$5,450,953 · 3
UH3$2,932,940 · 1
UG3$2,054,037 · 1
R01$2,003,505 · 1
M01$175,837 · 7

Top collaborators

Most similar at Weill Medical Coll Of Cornell Univ

Same institution · by research overlap

Others in their field

Top investigators on “Tumor”

Research focus

TumorMouse ModelLungPre-ClinicalImmuneLung AdenocarcinomaLesionPreventionNoduleMalignant Neoplasm Of LungPhenotypeMalignant NeoplasmsNon-Small-Cell Lung CarcinomaInsightNeoplastic CellSmokerSamplingInterceptImmunopreventionTumor MicroenvironmentImageAdenocarcinomaCohortMinimally Invasive

Grant awards (28)

CAP-IT Center for LNP RNA Immunoprevention$1,315,413
U54 · FY2025 · CA
Immunoregulatory role of lung-resident club cell factors in lung cancer$679,154
R01 · FY2025 · CA
Lung Cancer Vaccine$433,048
U54 · FY2025 · CA · contact PI
CAP-IT Center for LNP RNA Immunoprevention$1,060,438
U54 · FY2024 · CA
Immunoregulatory role of lung-resident club cell factors in lung cancer$645,197
R01 · FY2024 · CA
CAP-IT Center for LNP RNA Immunoprevention$1,098,880
U54 · FY2023 · CA
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$805,881
UH3 · FY2023 · CA · contact PI
Immunoregulatory role of lung-resident club cell factors in lung cancer$679,154
R01 · FY2023 · CA
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$234,178
UH3 · FY2023 · CA · contact PI
CAP-IT Center for LNP RNA Immunoprevention$1,180,595
U54 · FY2022 · CA
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$808,655
UH3 · FY2022 · CA · contact PI
Lung Cancer Vaccine$362,579
U54 · FY2022 · CA · contact PI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$238,958
UH3 · FY2022 · CA · contact PI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$845,268
UH3 · FY2021 · CA · contact PI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$249,999
UG3 · FY2021 · CA · contact PI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$836,730
UG3 · FY2020 · CA · contact PI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$130,578
UG3 · FY2020 · CA · contact PI
Intercepting progression from pre-invasive to invasive lung adenocarcinoma$836,730
UG3 · FY2019 · CA · contact PI
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER$1,173
M01 · FY2007 · RR · contact PI
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER$59,959
M01 · FY2006 · RR · contact PI
PH II STUDY/ PREOPERATIVE CELECOXIB/ PACLITAXEL/ CARBOPLATIN LUNG CANCER$13,775
M01 · FY2006 · RR · contact PI
A PILOT STUDY OF NY-ESO PLUS CPG 7909 AND MONTANIDE IN PATIENTS WITH CANCER$1,626
M01 · FY2006 · RR · contact PI
SAFETY AND IMMUNOLOGICAL EVALUATION OF NY-ESO-1 PLASMID DNA (PPJV7611) CANCER$37,168
M01 · FY2005 · RR
PH II STUDY/ PREOPERATIVE CELECOXIB/ PACLITAXEL/ CARBOPLATIN LUNG CANCER$15,305
M01 · FY2005 · RR
A PILOT STUDY OF NY-ESO PLUS CPG 7909 AND MONTANIDE IN PATIENTS WITH CANCER$8,745
M01 · FY2005 · RR
A PHASE III RANDOMIZED, GROWTH FACTOR RECEPTOR ZD1839 (IRESSA)IN LUNG CA$2,914
M01 · FY2005 · RR
Ph. II study/ preoperative celecoxib/ paclitaxel/ carboplatin lung cancer$32,774
M01 · FY2004 · RR
A Phase II Randomized, Growth Factor Receptor ZD1839 (IRESSA)in Lung CA$2,398
M01 · FY2004 · RR